

# Adaptation of Goal Attainment Scaling for Prader-Willi Syndrome: Development of a goal inventory for standardized implementation

Authors: Gunes Sevinc<sup>1</sup>, Sue Nesto<sup>1</sup>, Michelle George<sup>1</sup>, Chere Chapman<sup>1</sup>, Maria Picone<sup>2</sup>, Angeni Cordova<sup>2</sup>, Ameer Revana<sup>3</sup>, Ann Scheimann<sup>4</sup>, Deepan Singh<sup>5</sup>, Harold Van Bosse<sup>6</sup>, Jessica Duis<sup>7</sup>, Jennifer Miller<sup>8</sup>  
<sup>1</sup>Ardea Outcomes; <sup>2</sup>TREND Community; <sup>3</sup>Texas Children's Hospital, Baylor College of Medicine; <sup>4</sup>Johns Hopkins Hospital; <sup>5</sup>Maimonides Medical Center; <sup>6</sup>SSMHealth, Cardinal Glennon Children's Hospital, St. Louis University; <sup>7</sup>BioMarin Pharmaceutical Inc.; <sup>8</sup>University of Florida.

## Background

- Prader-Willi Syndrome (PWS) is a complex neuroendocrine disorder with notable heterogeneity in disease manifestation and symptom progression. To better understand the impact of treatments for children with PWS, we proposed to develop a draft goal inventory for individuals with PWS.
- Goal Attainment Scaling (GAS) is a personalized endpoint that quantifies the impact of an intervention on individualized goals. Clinicians, patients, and/or care providers collaboratively identify goals that are meaningful to the patient and develop unique scales for each identified goal.
- These semi-standardized goal inventories:
  1. Maximize the psychometric properties of the scales
  2. Streamline the goal scale development process, and
  3. Provide a shared language between the patient and the clinician.

## How Does Goal Attainment Scaling Works?



### Identify Goals

Clinician to facilitate interview for subject or caregiver to identify goals



### Build GAS Scales

Set the 5-point goal attainment scale for each identified goal



### Measure Attainment

Rate during follow-up whether the goals have been attained


### The Goal Attainment Scaling Process

1. Build a semi-standardized goal inventory
2. Train clinicians on GAS method
3. Conduct the goal setting visit
4. Assess goal attainment at follow up

## Methods



Five clinicians in the US with expertise in PWS participated in focus groups or an interview, and using semi-structured qualitative interview questions, the expert clinicians identified symptoms, challenges, and issues for people living with PWS and their families.



Interviews were recorded and transcribed; symptoms, challenges, and issues were then identified and coded using qualitative analysis software (NVivo 12).

## Results

### IMPACT ON THE PERSON LIVING WITH PWS

- Ability to work or go to school
- Requiring supervision
- Difficulty managing money
- Future planning
- Independence
- Relationships
- Vulnerability
- Not understanding boundaries
- Low self-esteem/feeling different
- Social isolation
- Susceptible to trauma
- Being treated differently
- Obsession with animals or babies
- Treatments and therapies (speech, braces, etc.)
- Other clinical diagnoses (depression, psychosis, etc.)

### IMPACT ON THE FAMILY

- Financial burden
- Parental and sibling stress and anxiety
- Dealing with unwanted behaviors
- Safety concerns and worry
- Providing routine; visual schedules, transitional cues
- Need for constant supervision
- Food security/locking food
- Accessing care
- Caregiver burden and burnout
- Long-term care planning
- Lack of available treatments and care protocols

- Age 0-2 years - low muscle tone, lack of interest in feeding (failure to thrive), sleep disorders, and global developmental delay.
- Age 3-8 years - weight gain, hip dysplasia, scoliosis, developmental delay, sleep disorders, and social-emotional and behavioral issues.
- Age 9 to adulthood - behavioral issues, hyperphagia, endocrine system issues, impacts on musculoskeletal functioning, and difficulties with sleep.
- Family impacts noted were parental and sibling stress and anxiety, the need for constant supervision, caregiver burnout, and the continual worry regarding safety.

	AGE 0-2	AGE 3-8	AGE 9-12	AGE 13-17	AGE 18+
DRAFT OF THE PWS GOAL INVENTORY	Narcolepsy Cataplexy Trouble sleeping or restless sleep Sleep apnea Excessive sleepiness Scoliosis Hip dysplasia Weight gain or fluctuations, obesity	Narcolepsy Cataplexy Trouble sleeping or restless sleep Sleep apnea Excessive sleepiness Scoliosis Hip dysplasia Weight gain or fluctuations, obesity	Narcolepsy Cataplexy Trouble sleeping or restless sleep Sleep apnea Excessive sleepiness Scoliosis Weight gain or fluctuations, obesity Low bone mineral density or osteoporosis	Narcolepsy Cataplexy Trouble sleeping or restless sleep Sleep apnea Excessive sleepiness Scoliosis Weight gain or fluctuations, obesity Low bone mineral density or osteoporosis	Narcolepsy Cataplexy Trouble sleeping or restless sleep Sleep apnea Excessive sleepiness Scoliosis Weight gain or fluctuations, obesity Low bone mineral density or osteoporosis
	Low muscle tone Difficulty breathing				
	Failure to thrive Lack of interest in eating or feeding Feeding tubes, over or under eating	Hyperphagia and food seeking	Hyperphagia and food seeking	Hyperphagia and food seeking	Hyperphagia and food seeking
			Constipation	Constipation	Constipation
			Pubertal issues Hypogonadism	Pubertal issues Hypogonadism	Pubertal issues Hypogonadism
	Undescended testicles Blood sugar high or low	Undescended testicles			
	Speech issues Delayed fine motor skills Decreased gross motor skills Global developmental delay	Blurred perception of reality Speech issues	Blurred perception of reality	Blurred perception of reality	Blurred perception of reality
	Language delay Verbal apraxia	Bed wetting Language delay Verbal apraxia	Verbal apraxia	Verbal apraxia	Verbal apraxia
	Affectionate	Inattentive	Verbal apraxia Breaking the law Social withdrawal Food related behavior problems Aggression Interrupting Impulsive	Verbal apraxia Breaking the law Social withdrawal Food related behavior problems Food related behavior problems Interrupting Impulsive	Verbal apraxia Breaking the law Social withdrawal Food related behavior problems Food related behavior problems Interrupting Impulsive
	<b>COLOR KEY - from the top</b>				
	Stealing Skin and rectal picking	Stealing Skin and rectal picking	Stealing Skin and rectal picking	Stealing Skin and rectal picking	Stealing Skin and rectal picking
	Physical Body Impact	Lying or making up stories	Lying or making up stories	Lying or making up stories	Lying or making up stories
	Respiratory Issues				
	Gastrointestinal Issues	Attention seeking behavior	Attention seeking behavior	Attention seeking behavior	Attention seeking behavior
	Food and Nutrition	Obsessive or hoarding behavior	Obsessive or hoarding behavior	Obsessive or hoarding behavior	Obsessive or hoarding behavior
	Endocrine System	Repetitive behavior	Repetitive behavior	Repetitive behavior	Repetitive behavior
	Cognitive & Developmental Delay	Stubbornness, tantrums, outbursts	Stubbornness, tantrums, outbursts	Stubbornness, tantrums, outbursts	Stubbornness, tantrums, outbursts
	Behavior	Rigidity or inflexibility Needs routine	Rigidity or inflexibility Needs routine	Rigidity or inflexibility Needs routine	Rigidity or inflexibility Needs routine

## Discussion & Conclusion



Critical to the drug development efforts, expert clinicians introduced a variety of other symptoms and manifestations of the disease that are not in the current diagnostic criteria but still impact the person living with PWS and their families.



The heterogeneity in symptom manifestations corroborates the value of GAS in capturing meaningful change following treatment, with the purpose of the inventory to help standardize GAS implementation in clinical development.



Patient reported symptoms are often underrepresented and thus limit opportunities to advance future management and treatment options. Qualitative research with patients and families is needed to further refine the inventory.

## Acknowledgements & References

Kiresuk, T. J., & Sherman, R. E. (1968). Goal attainment scaling: A general method for evaluating comprehensive community mental health programs. *Community mental health journal*, 4, 443-453.

This research was done in partnership with TREND Community and funded by Running for Research.



Download Poster

World Orphan Drug Conference

Due: Feb 29, 2024

**Authors:** Gunes Sevinc<sup>1</sup>, Sue Nesto<sup>1</sup>, Michelle George<sup>1</sup>, Chere Chapman<sup>1</sup>, Maria Picone<sup>2</sup>, Angeni Cordova<sup>2</sup>, Ameer Revana<sup>3</sup>, Ann Scheimann<sup>4</sup>, Deepan Singh<sup>5</sup>, Harold Van Bosse<sup>6</sup>, Jessica Duis<sup>7</sup>, Jennifer Miller<sup>8</sup>

<sup>1</sup> Ardea Outcomes

<sup>2</sup> TREND Community

<sup>3</sup> Texas Children's Hospital, Baylor College of Medicine

<sup>4</sup> Johns Hopkins Hospital

<sup>5</sup> Maimonides Medical Center

<sup>6</sup> SSMHealth, Cardinal Glennon Children's Hospital, St. Louis University

<sup>7</sup> BioMarin Pharmaceutical Inc.

<sup>8</sup> University of Florida

**Presenting Author:** Chere Chapman

**Title: Adaptation of Goal Attainment Scaling for Prader Willi Syndrome (PWS): Development of a goal inventory for standardized implementation**

**Purpose:** Goal Attainment Scaling (GAS) is a personalized endpoint that quantifies the impact of an intervention on individualized goals. Clinicians, in partnership with the patient and/or care provider, identify goals that are meaningful to the patient and develop unique scales for each identified goal. Semi-standardized goal inventories 1-) maximize the psychometric properties of the scales; 2-) streamline the goal scale development process; and 3-) provide a shared language between the patient and the clinician. Here we aimed to develop a goal inventory for individuals with Prader Willi Syndrome (PWS), a complex neuroendocrine disorder with notable heterogeneity in disease manifestation and symptom progression.

**Background:** Expert clinicians identified the symptoms, challenges and issues of individuals living with PWS and their caregivers through semi-structured qualitative interviews.

**Methods:** Five clinicians in the US with expertise in PWS participated in focus groups or an interview and were asked questions regarding the symptoms, challenges and issues for people living with PWS and their families, categorized by age (0-2; 3-8; 9-12; 13-17 and 18+). Interviews were recorded and transcribed; then symptoms, challenges and issues were identified and coded using qualitative analysis software (NVivo 12).

**Results:** For PWS patients aged 0-2, clinicians stated low muscle tone and other impacts on the musculoskeletal functioning and development, lack of interest in feeding (failure to thrive), sleep disorders, global developmental delay and effects on the endocrine system. For patients aged 3-8, they expressed weight gain, hip dysplasia, scoliosis, developmental delay, sleep disorders, social-emotional difficulties (e.g. trouble forming relationships and vulnerability) along with behavioral issues (e.g. tantrums, repetition, lying, stealing and skin picking). Clinicians identified similar symptoms from age 9 to adulthood including behavioral issues (e.g. tantrums, repetitive behaviors, and need for routine); as well as hyperphagia; endocrine system issues, impacts on the musculoskeletal functioning (e.g. scoliosis, osteoporosis, and mobility issues), GI concerns, and difficulties with sleep. Among family impacts,

parental and sibling stress and anxiety, the need for constant supervision, caregiver burnout and the continual worry regarding safety were noted.

**Conclusions:** Critical to the drug development efforts, expert clinicians introduced a variety of other symptoms and manifestations of the disease that are not in the current diagnostic criteria, but still impact the person living with PWS and their families. The heterogeneity in symptom manifestations corroborate the value of GAS in capturing meaningful change following treatment, with the goal inventory standardizing its implementation to enhance drug development efforts.